Currency In USD
| Previous Close | 1.47 |
| Open | 1.47 |
| Day High | 1.49 |
| Day Low | 1.43 |
| 52-Week High | 5.07 |
| 52-Week Low | 0.99 |
| Volume | 17,080 |
| Average Volume | 293,903 |
| Market Cap | 13.11M |
| PE | -0.88 |
| EPS | -1.64 |
| Moving Average 50 Days | 1.47 |
| Moving Average 200 Days | 3.09 |
| Change | -0.03 |
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
GlobeNewswire Inc.
Mar 06, 2026 11:15 PM GMT
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the transaction and recommends that stock
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
GlobeNewswire Inc.
Jan 27, 2026 1:00 PM GMT
Lisata regains full development rights to certepetide in the Greater China RegionBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company de
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
GlobeNewswire Inc.
Jan 21, 2026 12:00 PM GMT
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock B